BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

...same group had previously developed a SARS-CoV-2 fluorescence-based reporter.CD226...
...groups revealed in Immunity that loss of CD226...
...immunotherapy efficacy. An Inserm team found that CD226...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...triggers an inhibitory effect on immune cells and suppresses their function. When CD155 binds the CD226...
...between TIGIT and CD155 disrupts the immunosuppressive pathway while freeing up the ligand to bind CD226...
...between TIGIT and its ligand. Second, it frees the CD155 ligand to bind another receptor: CD226...
BioCentury | Jan 30, 2020
Company News

Lilly culls most of its clinical immuno-oncology pipeline

...which are in Phase I testing: a bispecific mAb targeting PD-1 and PD-L1, and a DNAM-1...
...of $6.1 billion. Lilly gained $2.75 to $142.67 on Thursday. Targets - IL-10 - Interleukin-10; DNAM-1...
BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

...Phase I or II trials. “Because PVRIG and TIGIT are parallel, non-redundant checkpoints in the DNAM-1...
...both for maximum T cell activation. The preclinical data for this was strong,” said Haitovsky. DNAM-1...
...Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Targets DNAM-1 (CD226...
BioCentury | Sep 29, 2017
Financial News

GRO Biosciences launches with $2.1M seed funding

Synthetic protein newco GRO Biosciences Inc. (Boston, Mass.) raised $2.1 million on Sept. 28 in a seed round led by Digitalis Ventures and Innovation Endeavors. The newco spun out of Harvard Medical School Professor George...
BioCentury | Sep 28, 2017
Company News

GRO Biosciences launches with $2.1M seed funding

Synthetic protein newco GRO Biosciences Inc. (Boston, Mass.) raised $2.1 million in a seed round led by Digitalis Ventures and Innovation Endeavors. The newco spun out of Harvard Medical School Professor George Church's lab with...
BioCentury | Sep 22, 2016
Emerging Company Profile

Base instincts

Although unnatural amino acids can help synthetic biologists create improved versions of therapeutic proteins, they have been difficult to integrate into conventional E.coli- based manufacturing systems. Synthorx is adding two synthetic bases, dubbed X and...
BioCentury | Jan 29, 2015
Targets & Mechanisms

Going TIGITal

...study the interaction between TIGIT and its co-stimulatory counter-receptor CD226.The team found that TIGIT and CD226...
...activate CD226, which stimulates effector T cells. In a mouse model of colon cancer, an anti-CD226...
...CD226 forms homodimers to interact with its ligand, PVR, on antigen-presenting cells. Stimulation of the CD226...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: T-cell immunoreceptor with Ig and ITIM domains (TIGIT)

...not significantly decrease tumor volume. In the model, an antibody targeting the TIGIT costimulatory receptor CD226...
BioCentury | Oct 28, 2010
Distillery Therapeutics

Indication: Transplantation

...inhibiting DNAM-1 could help treat GvHD. In irradiated mice receiving a bone marrow transplant, an anti-DNAM-1...
...compared with a control antibody (p<0.01). Next steps could include additional studies to determine how DNAM-1's...
Items per page:
1 - 10 of 11